Details of the Drug

General Information of Drug (ID: DMYXBV3)

Drug Name
Dulaglutide
Synonyms GLP-1 analog
Indication
Disease Entry ICD 11 Status REF
Type-2 diabetes 5A11 Approved [1]
Sequence
HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGGGGGGSGGGGSGGGGSAESKYGPPCPPCPA
PEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKP
REEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTL
PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLT
VDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 471 to 3294 mcg/L [2]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1-2 h [2]
Bioavailability
The bioavailability of drug is 42% [2]
Clearance
The clearance of drug is 0.142 L/h [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 3.75 days [4]
Metabolism
The drug is metabolized via the general protein catabolism pathways [3]
Vd
The volume of distribution (Vd) of drug is 3.09 L [3]
Cross-matching ID
DrugBank ID
DB09045
TTD ID
D03NAW

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucagon-like peptide 1 receptor (GLP1R) TTVIMDE GLP1R_HUMAN Agonist [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Type-2 diabetes
ICD Disease Classification 5A11
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Glucagon-like peptide 1 receptor (GLP1R) DTT GLP1R 1.25E-01 0.17 1.26
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7638).
2 Vangapandu HV, Jain N, Gandhi V: Duvelisib: a phosphoinositide-3 kinase delta/gamma inhibitor for chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017 May;26(5):625-632. doi: 10.1080/13543784.2017.1312338. Epub 2017 Apr 13.
3 FDA Approved Drug Products: Trulicity (dulaglutide) subcutaneous injection
4 Mode of administration of dulaglutide: implications for treatment adherence. Patient Prefer Adherence. 2016 Jun 2;10:975-82. doi: 10.2147/PPA.S82866. eCollection 2016.
5 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.